<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>vaccines on FinanClub</title>
    <link>https://finan.club/tags/vaccines/</link>
    <description>Recent content in vaccines on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 30 Jan 2024 09:06:25 +0000</lastBuildDate><atom:link href="https://finan.club/tags/vaccines/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Tue, 30 Jan 2024 09:06:25 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:76
Chances: Merck &amp;amp; Co., Inc. has been recognized for their strong performance and unwavering commitment to patients. With their estimated fair value of US$228 based on 2 Stage Free Cash Flow to Equity, there is potential for stock growth. KEYTRUDA has shown promising results in reducing the risk of death as adjuvant therapy for patients with RCC at an increased risk of recurrence following nephrectomy.</description>
    </item>
    
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Tue, 19 Dec 2023 09:06:54 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-135
Chances: AstraZeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. The additional supply of RSV shot for infants by AstraZeneca and Sanofi indicates a positive outlook for meeting winter demand.</description>
    </item>
    
  </channel>
</rss>
